Help us make childhood cancer universally survivable.
By giving monthly, you directly support our continued research into discovering effective and less toxic treatments for childhood cancer.
Support Our Lab
Our team is on a mission to make childhood cancer universally survivable!
The FDA approves on average 12 drugs every year to treat adult cancer, but has only approved 10 drugs to treat childhood cancer since 1978 (10 in 44 years for kids).
Since our inception in 2015, cc-TDI has pushed two drugs into three clinical trials to treat childhood cancer.
giving back childhood for
#GIVINGBACKCHILDHOOD
Latest News
cc-TDI Collaborates Globally with Atomwise
We proudly announce our global Artificial Intelligence (AI) collaboration with Atomwise, resulting in a new publication in the journal Scientific Reports. The paper, “AI is a viable alternative to high throughput screening: a 318 target study” comes from the AI computation drug design company, Atomwise in San Francisco. cc-TDI was among 282 Institutions across the world to work with Atomwise to use the AtomNet artificial intelligence model, which is a graph convolution network architecture, to predict compounds that dock to a given disease-related protein. cc-TDI previously published results of their target in the British Journal
State of Oregon Awards $1M in Equipment
Entinostat Moving Forward
Apply Now – Postdoctoral Fellowship at cc-TDI
In the Press
Current Research Projects
A dedicated research team
Our research team is exploring and testing state-of-the-art treatment options for the most urgent issues facing children with cancer.
Working in our own freestanding research institution allows us to act swiftly and nimbly to achieve results—bringing cost control, speed, purpose, and focus to translate effective treatments into the clinic. To get there, we perform basic science and translational research in our industrial modern lab site (a paint factory remodeled by Nike as an off-site creative space), adjacent to the Silicon Forest in Oregon.